|Day's Range||716.60 - 716.60|
|52 Week Range||716.60 - 716.60|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Children using GW Pharmaceutical's drug Epidiolex saw seizures drop by 40% and some ended completely. The New England Journal of Medicine published the Phase 3 study results this week.
A cannabis-based drug halved the frequency of convulsive seizures in sufferers of a rare, catastrophic form of epilepsy in a late-stage study funded by GW Pharmaceuticals Plc.
Here are Friday's top research calls, including upgrades for Chemours, Incyte and Toyota, and new coverage of Visteon.